AI-based platform for the development of cancer therapeutics
CompanyBioCopy AG, Basel, Switzerland
The company BioCopy specializes in the development of cancer therapeutics using AI-supported methods. The drug discovery platform enables effective screening for drug candidates that are able to connect the tumor cells with the body’s own immune cells by recognizing specific surface markers. The binding leads to the immune cell specifically killing the cancer cell without damaging the surrounding healthy cells. To engineer the highly complex antibody therapeutics, various technologies are combined in an automated process. The method shows high time and cost savings compared to conventional processes and is able to provide high-quality active ingredients on a large scale for industry. To date, the company has developed three drug development programs in solid tumors (bladder cancer, ovarian cancer, lung cancer) and two in blood cancers (acute myeloid lymphoma). In the future, BioCopy would like to expand the platform for screening drugs against neurological and immunological diseases. In summary, the method can help to accelerate drug development and optimize existing drug therapies.
We revolutionize the development of next-generation cancer drug candidates
info@biocopy.com
Added on: 04-23-2024
[1] https://www.biocopy.com/what-we-do
